Antibody-Mediated Oligodendrocyte Remyelination Promotes Axon Health in Progressive Demyelinating Disease
Overview
Neurology
Affiliations
Demyelination underlies early neurological symptoms in multiple sclerosis (MS); however, axonal damage is considered critical for permanent chronic deficits. The precise mechanisms by which axonal injury occurs in MS are unclear; one hypothesis is the absence or failure of remyelination, suggesting that promoting remyelination may protect axons from death. This report provides direct evidence that promoting oligodendrocyte remyelination protects axons and maintains transport function. Persistent Theiler's virus infection of Swiss Jim Lambert (SJL)/J mice was used as a model of MS to assess the effects of remyelination on axonal injury following demyelination in the spinal cord. Remyelination was induced using an oligodendrocyte/myelin-specific recombinant human monoclonal IgM, rHIgM22. The antibody is endowed with strong anti-apoptotic and pro-proliferative effects on oligodendrocyte progenitor cells. We used (1)H-magnetic resonance spectroscopy (MRS) at the brainstem to measure N-acetyl-aspartate (NAA) as a surrogate of neuronal health and spinal cord integrity. We found increased brainstem NAA concentrations at 5 weeks post-treatment with rHIgM22, which remained stable out to 10 weeks. Detailed spinal cord morphology studies revealed enhanced remyelination in the rHIgM22-treated group but not in the isotype control antibody- or saline-treated groups. Importantly, we found rHIgM22-mediated remyelination protected small- and medium-caliber mid-thoracic spinal cord axons from damage despite similar demyelination and inflammation across all experimental groups. The most direct confirmation of remyelination-mediated protection of descending neurons was an improvement in retrograde transport. Treatment with rHIgM22 significantly increased the number of retrograde-labeled neurons in the brainstem, indicating that preserved axons are functionally competent. This is direct validation that remyelination preserves spinal cord axons and protects functional axon integrity.
Targeting Remyelination in Spinal Cord Injury: Insights and Emerging Therapeutic Strategies.
Al Mamun A, Quan Z, Geng P, Wang S, Shao C, Xiao J CNS Neurosci Ther. 2024; 30(12):1-15.
PMID: 39723448 PMC: 11669846. DOI: 10.1111/cns.70193.
The Antibody Dependant Neurite Outgrowth Modulation Response Involvement in Spinal Cord Injury.
Capuz A, Karnoub M, Osien S, Rose M, Meriaux C, Fournier I Front Immunol. 2022; 13:882830.
PMID: 35784350 PMC: 9245426. DOI: 10.3389/fimmu.2022.882830.
Greenberg B, Bowen J, Alvarez E, Rodriguez M, Caggiano A, Warrington A Mult Scler J Exp Transl Clin. 2022; 8(2):20552173221091475.
PMID: 35496758 PMC: 9052243. DOI: 10.1177/20552173221091475.
Allanach J, Farrell 3rd J, Mesidor M, Karimi-Abdolrezaee S Mult Scler. 2021; 28(1):29-48.
PMID: 33870797 PMC: 8688986. DOI: 10.1177/13524585211008760.
Relapse recovery: The forgotten variable in multiple sclerosis clinical trials.
Kantarci O, Zeydan B, Atkinson E, Conway B, Castrillo-Viguera C, Rodriguez M Neurol Neuroimmunol Neuroinflamm. 2019; 7(2).
PMID: 31848231 PMC: 6943367. DOI: 10.1212/NXI.0000000000000653.